Home
Diseases
Type 2 Diabetes

Type 2 Diabetes

Disease

Disease Profile

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction causing hyperglycemia. It is the most common type of diabetes.

Category: Endocrine, nutritional and metabolic diseases
Prevalence: About 38.4 million people in the U.S. have diabetes and 90-95% have type 2 diabetes

ICD Codes

Related News

Living Insulin Implant Shows Promise as Millions Still Lack Access to Diabetes Medication

Jun 29, 2026

A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.

Posture-Driven Retinal Signals May Predict Diabetic Retinopathy Progression

Jun 15, 2026

New research shows posture-driven retinal vascular changes can predict diabetic retinopathy progression, with smartphone-based imaging detecting early microvascular dysfunction. A five-year study found abnormal arteriolar tortuosity during postural shifts increased progression risk over two-fold.

Sequel's twiist AID System Shows Significant Blood Sugar Improvements in Type 2 Diabetes Trial

Jun 08, 2026

Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.

Tandem Diabetes Wins CE Mark for AID Systems in Europe After FDA Pregnancy Approval

Jun 05, 2026

Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.

Blood Pressure Drug Class Linked to Worse Kidney Outcomes in Diabetic Patients, Studies Show

Jun 05, 2026

New research presented at the ERA Congress found DCCB blood pressure medications were associated with a 33% increased risk of major adverse kidney events in Type 2 diabetes patients also receiving RAS and SGLT2 inhibitors. A separate study revealed that diabetic nephropathy patients exhibit the most severe biochemical disturbances, including markedly elevated glycemic indices and significantly impaired renal function compared to other groups.

Diabetes Tech Companies Launch Enhanced CGM Systems and Insulin Delivery Platforms

Jun 04, 2026

Diabetes technology companies Dexcom, Insulet, and Sequel/Senseonics announced major product launches and algorithm updates. Dexcom is acquiring Nutrisense and launching an enhanced Stelo app, Insulet is rolling out an updated Omnipod 5 algorithm with lower glucose targets and Abbott compatibility, and Sequel/Senseonics have fully launched the Eversense 365 CGM with the twiist insulin delivery system in the U.S.

MannKind Wins FDA Approval for Afrezza Inhaled Insulin in Children Ages 6 and Older

May 31, 2026

MannKind Corporation announced FDA approval of Afrezza inhaled mealtime insulin for pediatric patients with diabetes ages 6 and older. The approval makes Afrezza the first needle-free mealtime insulin alternative for children in over 100 years. Eligible patients can access Afrezza for $35 or less per month.

MannKind's Afrezza Inhaled Insulin Approved for Children; Updated Label Provides New Dose Guidance for Adults

May 30, 2026

FDA approves MannKind's Afrezza inhaled insulin for children aged 6+ with type 1 and type 2 diabetes. Separately, an updated label provides new starting dose guidance for adults switching from injections or insulin pumps.

NICE Updates Type 2 Diabetes Guidance for Earlier SGLT-2 Inhibitor Use; SGLT2 Inhibitors Also Linked to Survival Benefit in Takotsubo Syndrome

May 28, 2026

NICE updates type 2 diabetes guidance in England, recommending earlier use of SGLT-2 inhibitors and GLP-1 receptor agonists. Separately, a study finds SGLT2 inhibitors improve survival in Takotsubo syndrome patients.

Sugary Drinks Linked to Anxiety in Adolescents; Parental Substance Use Shapes Teen Consumption

May 25, 2026

A study links sugary drink consumption to anxiety in adolescents, while separate research shows parental substance use patterns strongly influence teen consumption, with authoritative parenting styles offering protective effects.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07606066	A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies	RECRUITING
NCT07605390	RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)	NOT_YET_RECRUITING	NA
NCT07602036	Type 2 Diabetes and Pregnancy a Single-arm Interventional Study	NOT_YET_RECRUITING	NA
NCT07599852	MEDBRIDGE-Guided NCM/CHW Post-Discharge Support for High-Risk T2D Patients	NOT_YET_RECRUITING	NA
NCT07598773	BETA: Study in Prediabetes Type 2 Diabetes	ENROLLING_BY_INVITATION
NCT07598266	Evaluation of a Structured Nutrition Educational Program Among Patients With Type 2 Diabetes	NOT_YET_RECRUITING	NA
NCT07587918	Sweet & Sour: Dietary Acid Load in Type 2 Diabetes and Kidney Disease Across Sex and Ethnic Groups	NOT_YET_RECRUITING	NA
NCT07587151	Remote Pharmacy Services Plus Continuous Glucose Monitoring in an Underserved Population	COMPLETED	NA
NCT07585630	A1Cantus vs. Placebo	NOT_YET_RECRUITING	PHASE2
NCT07583355	Interdisciplinary Counselling in DIAbetes	RECRUITING	NA